At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 14, 2026 at 06:00 ET
Spero Therapeutics in-licensed global rights (ex-China) to SP001 (IBI355), a third-generation anti-CD40L antibody, from Innovent Biologics. The deal includes up to ~$1.1B in total milestones plus tiered royalties, and Spero plans a Phase 2 trial in IgG4-RD starting Q2 2027. This transaction transforms Spero's pipeline from infectious disease into immunology, but the asset is preclinical for Spero's lead indication and carries significant development risk.
- Spero receives exclusive global rights (ex-Greater China) to SP001 (IBI355), a third-generation Fc-silent anti-CD40L antibody.
- Total deal value up to ~$1.1B in development, regulatory, and commercial milestones plus tiered royalties on net sales.
- Spero plans to initiate a Phase 2 trial in IgG4-RD in Q2 2027; Innovent plans a Phase 2 in Sjögren's disease in China by early 2027.
- SP001 has completed Phase 1 SAD/MAD healthy volunteer studies and a Phase 1b MAD study in SjD (data presented at EULAR 2026).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access